Secondary anchor targeted cell release.
Ali Ansari, Felipe T Lee-Montiel, Jennifer R Amos1
1Department of Bioengineering, University of Illinois at Urbana Champaign, Urbana, Illinois, 61801.
Biotechnology and Bioengineering
|May 27, 2015
Summary
Researchers developed a gentle cell capture platform for personalized medicine. This system uses surface functionalization for efficient cell isolation and release, aiding biomarker analysis.
Area of Science:
- Biotechnology
- Materials Science
- Cell Biology
Background:
- Personalized medicine requires tailored therapies based on individual cellular biomarkers.
- Efficient and gentle cell isolation methods are crucial for preserving these biomarkers.
- Current cell isolation techniques may disrupt cellular integrity, limiting their use in personalized medicine.
Purpose of the Study:
- To develop a novel platform for gentle cell capture and release.
- To optimize surface functionalization for high efficiency and specificity in cell isolation.
- To enable cell isolation for downstream biomarker analysis in personalized medicine.
Main Methods:
- A glass surface was functionalized with APTES, d-desthiobiotin, and streptavidin.
- Biotinylated antibodies (mCD11b, hIgG) were used for capturing specific cell lines (macrophages, cancer cells).
- Surface functionalization components were optimized to enhance cell capture and enable release upon biotin treatment.
Main Results:
- The optimized platform achieved cell capture on 80% of the functionalized surface.
- The system demonstrated successful cell release upon biotin treatment.
- The platform showed an ability to capture 50% of target cells from a mixed-cell population.
Conclusions:
- The developed platform facilitates gentle and efficient cell capture and release.
- This advancement is a significant step towards creating effective cell isolation tools for personalized medicine.
- The system's ability to preserve cellular biomarkers supports its application in tailored therapeutic strategies.
Related Concept Videos
Modified-Release Drug Delivery Systems: Site-Targeted
130
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
130
Targeted Cancer Therapies
9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.2K
GPI Anchoring of Proteins in the ER Membrane
6.0K
GPI-anchoring is a post-translational, reversible protein modification that is ubiquitous in eukaryotes. Such proteins are primarily present on the exoplasmic leaflet of the plasma membrane.
GPI-anchor structure
A sequence of 11 enzymatic reactions results in the synthesis of the complete GPI anchor consisting of a hydrophobic and a hydrophilic portion. The hydrophobic portion comprises phosphatidylinositol, while the hydrophilic part comprises polar groups like phosphoethanolamine,...
GPI-anchor structure
A sequence of 11 enzymatic reactions results in the synthesis of the complete GPI anchor consisting of a hydrophobic and a hydrophilic portion. The hydrophobic portion comprises phosphatidylinositol, while the hydrophilic part comprises polar groups like phosphoethanolamine,...
6.0K
Tail-anchoring of Proteins in the ER Membrane
4.1K
Tail-anchored, or TA, proteins are estimated to make up to 3-5% of membrane proteins found in the eukaryotic cell. Such proteins have a single transmembrane domain located approximately 30 amino acid residues upstream from the C-terminal end. As a result, the signal recognition particle (SRP) cannot guide a TA protein to the ER membrane for cotranslational insertion. Hence, they are integrated into the ER membrane post-translationally using their C-terminal end as the anchor. TA proteins...
4.1K
Site-Targeted Drug Delivery Systems: Polymeric Carriers
125
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
125
Modified-Release Drug Delivery Systems: Stimuli-Activated
137
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
137


